FDA Clears Path for Generic Rectiv Ointment
Published Date: 6/26/2026
Notice
Summary
The FDA has decided that RECTIV (nitroglycerin) ointment, 0.4%, wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules, so patients and pharmacies won’t face shortages or price spikes. If you’re a drug maker or user, this is good news for steady access and affordable options.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Generic Approvals May Continue
The FDA determined on publication June 26, 2026 that RECTIV (nitroglycerin) ointment, 0.4% was not withdrawn for reasons of safety or effectiveness. Because of that determination, FDA will not begin procedures to withdraw approval of approved abbreviated new drug applications (ANDAs) that refer to RECTIV, and additional ANDAs may be approved if they meet legal and regulatory requirements.
Product Remains on Discontinued List
FDA will continue to list RECTIV (nitroglycerin) ointment, 0.4% in the Orange Book's "Discontinued Drug Product List," indicating the product is discontinued from marketing for reasons other than safety or effectiveness. AbbVie notified FDA of the discontinuation on March 27, 2026; the NDA was initially approved on June 21, 2011.
Labeling Updates May Be Requested
If FDA determines that labeling for RECTIV should be revised to meet current standards, the Agency will advise ANDA applicants to submit updated labeling. Aurobindo Pharma USA submitted a citizen petition on April 23, 2026, prompting this determination.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19654, Naveed Aslam: Final Debarment Order
The FDA has permanently banned Dr. Naveed Aslam from working with any drug companies because he was convicted of a serious crime related to drug regulations. He didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on September 25, 2026. Dr. Aslam can apply to end this ban anytime, but it won’t be easy or quick.
2026-19660, Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments
The FDA is gearing up to renew the Biosimilar User Fee Act, which helps fund the review of biosimilar drug applications. This affects drug makers and the public by ensuring faster, smoother approval processes from 2028 to 2032. They’re hosting a public meeting on October 26, 2026, and want your comments by November 25, 2026, to shape the future of this important program.
Previous / Next Documents
Previous: 2026-12952, Production Activity Not Authorized; Foreign-Trade Zone (FTZ) 75; Catalina Components, Inc.; (Vehicle Parts); Chandler, Arizona; Correction
Catalina Components, Inc. in Chandler, Arizona, didn’t get approval to start production in Foreign-Trade Zone 75, and this notice fixes a small mistake in the official paperwork. The correction changes the docket number to the right one, making sure the record is clear and accurate. No new money or timing changes—just a tidy update to keep things straight!
Next: 2026-12954, Harbert Mezzanine Partners II SBIC, L.P.; Surrender of License of Small Business Investment Company
Harbert Mezzanine Partners II SBIC, L.P. has officially given up its license to operate as a Small Business Investment Company. This means they won’t be making new investments under this program anymore. The change is effective immediately, so small businesses looking for funding from them will need to look elsewhere.